S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Vermillion Scores Patent on Cancer Test (VRML)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Shares of diagnostics company Vermillion Inc. (NASDAQ: VRML) have jumped more than 20% this morning following the company’s announcement of a patent approval for another of its biomarkers used to diagnose ovarian cancer. Today’s approval covers the use of “Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.”

The company’s CEO said:

The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1®, and offers creative new options to detect and manage this silent killer.

Vermillion’s shares are up 22% at $2.08 in a 52-week range of $0.97-$7.60. Volume is very heavy, already at 5x the daily average of about 522,000 shares traded.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Why The Money Guy's 25% Savings Rule Actually Starts at 15%
Ian Cooper |

Why The Money Guy's 25% Savings Rule Actually Starts at 15%
Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending
Drew Wood |

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

Continue Reading

Paul Ausick |

Supreme Court Justices Unanimous on Denying Patents for Human Genes

ThinkstockThe U.S. Supreme Court issued a unanimous 9-0 ruling today denying patent protection from human genes isolated from the body.…
Ovarian Cancer Treatment Takes the Next Big Step and Hits the Fast Track
Chris Lange |

Ovarian Cancer Treatment Takes the Next Big Step and Hits the Fast Track

Now, Mereo BioPharma is taking steps towards a solution to ovarian cancer with its most recent update from the FDA.
Jon C. Ogg |

Did Endocyte Just Become Buyout Bait?

Endocyte is trading like it is being acquired. This is proof that any biotech with great cancer drug news can…
Jon C. Ogg |

How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again

Clovis Oncology shares saw a massive gain on Tuesday, on the heels of news that the FDA had granted it…
How Clovis Scored Big on a Milestone FDA Approval
Chris Lange |

How Clovis Scored Big on a Milestone FDA Approval

Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food…
Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study
Chris Lange |

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support…
Lee Jackson |

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug…
Why Tesaro Is Skyrocketing
Chris Lange |

Why Tesaro Is Skyrocketing

Tesaro, Inc. (NASDAQ: TSRO) is watching its shares make a significant gain on Wednesday after the company released positive late-stage…
Lee Jackson |

3 Stocks to Buy Now With Up to 100% or More Upside Potential

These are three totally different plays that all have huge upside potential for investors able to commit some of their…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618